Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household ...

New research reveals a potentially effective COVID-19 pill is in the works. Here’s what infectious disease experts want you ...

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

Results suggest potential effectiveness in settings such as nursing homes ...

A Prescription Drug User Fee Act target date of June 16, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Please provide your email address to receive an email when new articles are posted on . The Infectious Disease Society of America suggests that immunocompromised patients take the COVID-19 prevention ...

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.

Although the general population now has at least some immunity against COVID-19, the consequences of severe disease are frequently overlooked for certain patient populations, such as those with ...

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...

We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...